The agritech industry is editing plant genomes to feed a growing population, expand the produce aisle, and make tastier, more convenient food products.

The purchase adds long-read sequencing to Illumina’s portfolio.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.

LabCorp might be able to charge a licensing fee to any scientists who wish to sequence the gene HOMER1 in people who may have autism.

Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.

An investigation of 2.7 million patent submissions in the U.S. finds gender disparities throughout the application process.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.